A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer

I5B-MC-JGDN -

The main purpose of this study is to evaluate the safety of different doses of olaratumab and to determine which dose should be used for future pediatric studies. The present study is open to children with advanced cancer or cancer that has spread to another part of the body. The study has two parts. In each part, a specific dose of olaratumab will be given alone for 21 days and followed by one of three standard chemotherapy regimens. Participants will enroll in one part only.

Trial Summary

Age Range
≤17 years
Conditions the trial is for
Pediatric Solid Tumors
What the trial is testing?
Doxorubicin, Ifosfamide, Irinotecan, Olaratumab, Vincristine
Could I receive a Placebo?
No
Enrollment Goal
68
Trial Dates
Aug 29, 2016 - Apr 3, 2019
How long will I be in the trial?
Your participation could last up to 3 years depending on how you and your tumor respond.
Trial Phase
I

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.